RCT

Shorter Romosozumab Course Non-Inferior for Postmenopausal Bone Loss

This non-inferiority randomized controlled trial published in The Lancet found that three months of romosozumab produced bone mineral density gains at the total hip that were non-inferior to the standard twelve-month course in postmenopausal women with osteoporosis. The findings suggest that a shorter treatment duration may be a viable option, potentially improving tolerability and adherence for women in early postmenopause who need bone-protective therapy.